Deferred Income Tax Expense (Benefit) of Silence Therapeutics plc from 31 Dec 2022 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Silence Therapeutics plc annual and quarterly Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2022 to 31 Dec 2025.
  • Silence Therapeutics plc Deferred Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $0, a 100% decline year-over-year.
  • Silence Therapeutics plc annual Deferred Income Tax Expense (Benefit) for 2025 was $11,000, a 99% decline from 2024.
  • Silence Therapeutics plc annual Deferred Income Tax Expense (Benefit) for 2024 was $845,000, a 12% decline from 2023.
  • Silence Therapeutics plc annual Deferred Income Tax Expense (Benefit) for 2023 was $956,000, a 39% increase from 2022.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Change (%)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)

Silence Therapeutics plc Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $11,000 -$834,000 -99% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $845,000 -$111,000 -12% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $956,000 +$268,000 +39% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $688,000 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY

Silence Therapeutics plc Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $0 -$244,000 -100% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q1 2024 $244,000 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.